CoChat

GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Growth hormone (GH) is an essential regulator of growth, body composition and fuel metabolism and, consequently, GH secretion is under the feedback control of numerous nutritional and endocrine mediators. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to exert pleiotropic effects, including stimulation of the activity of the hypothalamic-pituitary-adrenal axis. As GLP-1RAs exert multiple metabolic effects, we hypothesised that they may also affect the secretion of GH and examined the effect of a short-acting and a long-acting GLP-1 RA on GH secretion. METHODS: This is a post hoc analysis of data from clinical trials. Two separate single-group open-label clinical trials were carried out in the ambulatory care setting with a duration of 1 and 21 days, respectively. Healthy adult male and female volunteers with no chronic illnesses or use of daily medicines were recruited for the study. The two interventions were: study 1, single dose of 10 µg exenatide administered subcutaneously (s.c.); study 2, 0.6 mg liraglutide administered s.c. once daily for 21 days. RESULTS: Administration of a single dose of exenatide (study 1) caused a clear increase in GH levels, peaking between 60 and 120 min post-administration. There was also a small but statistically significant decrease in luteinising hormone and testosterone levels 120 min after exenatide dosing. Administration of the long-acting GLP-1RA liraglutide daily for 21 days (study 2) elicited an increase in GH levels with no change in insulin-like growth factor-1 (IGF-1) concentrations after 3 weeks of treatment. CONCLUSIONS: The results show that the administration of GLP-1RAs may elicit an increase in growth hormone levels. GLP-1 signalling may be a novel mechanism of regulation of GH secretion. This finding needs to be replicated in the placebo-controlled trial. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02089256 and NCT03160261.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01381-w

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A Growth hormone (GH) pre-treatment and peak value after administration of 10 µg exenatide subcutaneously (s.c.) Asterisk indicates a significant difference at *p < 0.05 (Wilcoxon signed-rank test). B GH values at pre-specified sampling points depicted as timeline. Asterisk indicates a significant difference at *p < 0.05 (Dunn’s test). C GH levels at baseline and after acute and chronic treatment with 0.6 mg liraglutide s.c. Asterisks indicate a significant difference at *p < 0.05, **p < 0.01 (Dunn’s test). D Insulin-like growth factor 1 (IGF-1) levels at baseline, and after acute and chronic treatment with 0.6 mg liraglutide s.c. Asterisk indicates a significant difference at *p < 0.05 (Tukey test). GH data are depicted as the median with range; IGF-1 data are given as the mean with standard deviation (SD). Reference values: GH < 5 ng/mL; IGF-1 116–353 µg/L
Fig. 1 A Growth hormone (GH) pre-treatment and peak value after administration of 10 µg exenatide subcutaneously (s.c.) Asterisk indicates a significant difference at *p < 0.05 (Wilcoxon signed-rank test). B GH values at pre-specified sampling points depicted as timeline. Asterisk indicates a significant difference at *p < 0.05 (Dunn’s test). C GH levels at baseline and after acute and chronic treatment with 0.6 mg liraglutide s.c. Asterisks indicate a significant difference at *p < 0.05, **p < 0.01 (Dunn’s test). D Insulin-like growth factor 1 (IGF-1) levels at baseline, and after acute and chronic treatment with 0.6 mg liraglutide s.c. Asterisk indicates a significant difference at *p < 0.05 (Tukey test). GH data are depicted as the median with range; IGF-1 data are given as the mean with standard deviation (SD). Reference values: GH < 5 ng/mL; IGF-1 116–353 µg/LCC BY-NC · PubMed Central
Fig. 2 Correlation between GH peak values and change in glucose levels in the exenatide experiment (study 1). Pearson correlation, p = 0.207
Fig. 2 Correlation between GH peak values and change in glucose levels in the exenatide experiment (study 1). Pearson correlation, p = 0.207CC BY-NC · PubMed Central
Fig. 3 A Luteinising hormone (LH) levels at baseline and at 120 min after administration of 10 µg exenatide. B Testosterone levels at baseline and at 120 min after administration of 10 µg exenatide. Asterisk indicates a significant difference at *p < 0.05 (Tukey test). Data are depicted as the mean with SD. Reference values: LH 1.7–8.6 U/L; testosterone 6.68–29.0 nmol/L
Fig. 3 A Luteinising hormone (LH) levels at baseline and at 120 min after administration of 10 µg exenatide. B Testosterone levels at baseline and at 120 min after administration of 10 µg exenatide. Asterisk indicates a significant difference at *p < 0.05 (Tukey test). Data are depicted as the mean with SD. Reference values: LH 1.7–8.6 U/L; testosterone 6.68–29.0 nmol/LCC BY-NC · PubMed Central
Fig. 4 Change in prolactin (A) and copetine (B) levels. Asterisks indicate a significant difference at *p < 0.05 and **p < 0.01 (Tukey test). Data are depicted as mean with SD. Reference values: prolactin (males) 86–324 mU/L, (females) 102–496 mU/L; copeptine 1.0–28.2 pmol/L
Fig. 4 Change in prolactin (A) and copetine (B) levels. Asterisks indicate a significant difference at *p < 0.05 and **p < 0.01 (Tukey test). Data are depicted as mean with SD. Reference values: prolactin (males) 86–324 mU/L, (females) 102–496 mU/L; copeptine 1.0–28.2 pmol/LCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 36

Metadata

Authors
Heinla, K., Vasar, E., Reppo, I., Sedman, T., & Volke, V.
Affiliations
  • University of Tartu (EE)
  • Tartu University Hospital (EE)
Corresponding author
Volke, Vallo
Venue
Diabetes Therapy
Published
2023-02-17
Volume
14
Issue
4
Pages
777-786
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4321169573
Cited by
30
References
31
Citations by year
2026: 12 · 2025: 10 · 2024: 8
FWCI
6.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Eesti Teadusagentuur (IUT20-41)
  • Horizon 2020 Framework Programme (668989)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
GLP-1 receptor agonists, growth hormone secretion, exenatide, liraglutide, hypothalamic-pituitary-adrenal axis, luteinizing hormone, testosterone, insulin-like growth factor I, healthy volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers. https://app.cochat.ai/papers/10.1007/s13300-023-01381-w
The paper
Heinla, K., Vasar, E., Reppo, I., Sedman, T., & Volke, V. (2023). GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01381-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.